# Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

> **NCT07471815** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer Triple Negative Breast Cancer

## Interventions

- **DRUG:** Camrelizumab + Risedronate Sodium + Chemotherapy

## Key facts

- **NCT ID:** NCT07471815
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-03-04
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07471815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07471815, "Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07471815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*